Chief Scientific Officer

Emeritus Professor Dr Yuen Kah Hay

Dr Yuen Kah Hay, an esteemed Emeritus Professor, brings over four decades of experience in the pharmaceutical industry. He is one of the pioneers of bioequivalence studies in Malaysia and is well recognized for his role in developing the generic pharmaceutical industry in Malaysia.

 

His expertise spans drug formulation, product development and clinical research. As an academic, he has mentored many generations of pharmacists in Malaysia and abroad.

 

Dr Yuen is one of the earliest Malaysians to study palm oil phytonutrients, with a keen eye for the potential of tocotrienols. He developed a patented formulation for enhanced absorption of tocotrienols. He led the human studies which showed the neuroprotective and liver protective effects of tocotrienols.

 

He was listed as World’s Top 2% Scientist in 2020, the Top 2% most cited scientist in the world in 2021 and the Top 2% in the World in Their Respective Fields in 2022 by Stanford University. He was listed as Top 2% in the world again in 2023 for both categories of career-long and number of citations obtained in 2022. 

 

With his vast knowledge, remarkable achievements, and global recognition, Dr Yuen Kah Hay continues to propel AvantHealth forward, bringing transformative solutions to consumers
worldwide.

Other Team Members

General Manager
Over 20 years of pharmaceutical research & development and product development experience.

Expert in developing and commercialising new products from lab to market.

Scientific & Regulatory Affairs Manager

Over 15 years of experience in developing and monitoring clinical studies.
 
Specialised in USFDA and EU regulatory compliance for product development and commercialisation.

Quality Manager

Over 15 years of experience in pharmaceutical chemistry and technology.
 
Expert in analytical chemistry to meet stringent quality standards.